176 - Late Breaking Abstracts: COVID-19 & Friends

Moderator(s)

• 

  David Lindholm, MD FACP FIDSA (he/him/his)

  Interim Associate Dean for Regional Education
  Department of Medicine, Uniformed Services University of the Health Sciences; Brooke Army Medical Center
  San Antonio, TX, United States
• 

  Rajesh Gandhi, MD (he/him/his)

  Professor of Medicine
  Harvard Medical School
  Boston, MA, United States

Presentations:

• 1:45 PM – 1:57 PM US ET

  Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
  

  Presenting Author: Deidre Wilkins, BSC (she/her/hers) – Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca

  Co-Author: Ulrika Wählby Hamrén, PhD – AstraZeneca, Gothenburg, Sweden

  Co-Author: Yue Chang, PhD – AstraZeneca

  Co-Author: Joseph B. Domachowske, MD – SUNY Upstate Medical University

  Co-Author: Janet A. Englund, MD – Seattle Children’s Hospital

  Co-Author: William J. Muller, MD – Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine

  Co-Author: Amanda Leach, MD – AstraZeneca

  Co-Author: Tonya L. Villafana, PhD, MPH – AstraZeneca

  Co-Author: Elizabeth J. Kelly, PhD – AstraZeneca
• 1:57 PM – 2:09 PM US ET

  COVID-19 mRNA Vaccination Reduces the Occurrence of Post-COVID Conditions in U.S. Children Aged 5-17 Years Following Omicron SARS-CoV-2 Infection, July 2021-September 2022
  

  Presenting Author: Anna R. Yousaf, MD (she/her/hers) – Centers for Disease Control and Prevention

  Co-Author: Josephine Mak, MPH – Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention

  Co-Author: Lisa Gwynn, MBA, MSPH – Miller School of Medicine, University of Miami

  Co-Author: Robin Bloodworth, PhD MPH – Abt Associates

  Co-Author: Ramona Rai, MPH – Abt Associates

  Co-Author: Zuha Jeddy, MPH – Abt Associates

  Co-Author: Lindsay B. LeClair, MS, MPH – Abt Associates

  Co-Author: Laura Edwards, MPH – Abt Associates

  Co-Author: Lauren E.W. Olsho, PhD – Abt Associates

  Co-Author: Gabriella Newes-Adeyi, PHD, MPH – Abt Associates

  Co-Author: Alexandra F. Dalton, PhD (she/her/hers) – Centers for Disease Control and Prevention

  Co-Author: Manjusha Gaglani, MBBS – Baylor Scott & White Health

  Co-Author: Sarang K. Yoon, DO, MOH – University of Utah School of Medicine

  Co-Author: Kurt Hegmann, MD, MPH – U.Utah

  Co-Author: Katherine Ellingson, PhD – University of Arizona

  Co-Author: Leora R. Feldstein, PhD, MSc (she/her/hers) – Centers for Disease Control and Prevention

  Co-Author: Angela P. Campbell, MD, MPH – Centers for Disease Control and Prevention

  Co-Author: Amadea Britton, MD/SM – Centers for Disease Control and Prevention

  Co-Author: Sharon Saydah, PhD – Centers for Disease Control and Prevention
• 2:09 PM – 2:21 PM US ET

  Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
  

  Presenting Author: Michael G. Ison, MD MS (he/him/his) – National Institutes of Health

  Co-Author: Alberto Papi, MD – University of Ferrara, St. Anna University Hospital, Ferrara, Italy

  Co-Author: Joanne M. Langley, MD – Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Canada

  Co-Author: Dong-Gun Lee, PhD MD – The Catholic University of Korea, Seoul, South Korea

  Co-Author: Isabel Leroux-Roels, PhD MD – Ghent University and Ghent University Hospital, Ghent, Belgium

  Co-Author: Federico Martinon-Torres, MD, PhD, Assoc. Prof – Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

  Co-Author: Tino F. Schwarz, Prof. Dr. MD – Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany

  Co-Author: Richard N. Van Zyl-Smit, PhD MD – University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa

  Co-Author: Susanna Cuadripani, MD – GSK, Stevenage, Hertfordshire, United Kingdom

  Co-Author: Nancy Dezutter, PhD, PharmD – GSK, Wavre, Belgium

  Co-Author: Olivier Gruselle, MS – GSK, Wavre, Belgium

  Co-Author: Laurence Fissette, Master in Statistics – GSK, Wavre, Belgium

  Co-Author: Marie-Pierre David, Master in Statistics – GSK, Wavre, Belgium

  Co-Author: Aurélie Olivier, PhD – GlaxoSmithKline Biologicals

  Co-Author: Marie Van Der Wielen, MD – GSK, Wavre, Belgium

  Co-Author: Dominique Descamps, MD – GSK, Wavre, Belgium
• 2:21 PM – 2:33 PM US ET

  Use of Paxlovid for Treatment of Acute COVID-19 and Occurrence of Post-COVID Conditions among Children and Adults at High-Risk for Severe COVID-19, April 1 - December 31, 2022.
  

  Presenting Author: Alexandra F. Dalton, PhD (she/her/hers) – Centers for Disease Control and Prevention

  Co-Author: Sarah Baca, B.Sc. Environmental Science, B.Sc. Mathematics – GAP Solutions Inc.

  Co-Author: Julia Raykin, PhD – CDC

  Co-Author: Cria Perrine, PhD – CDC

  Co-Author: Tegan Boehmer, PhD, MPH – Centers for Disease Control and Prevention

  Co-Author: Emilia Koumans, MD MPH – CDC

  Co-Author: Priti Patel, MD, MPH – Centers for Disease Control and Prevention

  Co-Author: Sharon Saydah, PhD – Centers for Disease Control and Prevention
• 2:33 PM – 2:45 PM US ET

  CoviLiv™, a Novel Intranasal Live-Attenuated COVID-19 Vaccine Candidate, Induces Robust Humoral and Cellular Immunity in First-In-Human Clinical Trial CDX-CoV-001
  

  Presenting Author: Johanna K. Kaufmann, PhD (she/her/hers) – Codagenix Inc.

  Co-Author: Keri Wyllie, MPA – Codagenix Inc.

  Co-Author: Yiwen Zhao, PhD – Codagenix Inc.

  Co-Author: Lasmy Tea, MS, MPH – Codagenix Inc.

  Co-Author: Sybil Tasker, MD, MPH, FIDSA – Codagenix Inc.

  Co-Author: Leena R. Yeolekar, PhD – Serum Institute of India Pvt. Ltd.

  Co-Author: Rajeev Dhere, PhD – Serum Institute of India Pvt. Ltd.

  Co-Author: Steffen Mueller, PhD – Codagenix, Inc
• 2:45 PM – 2:57 PM US ET

  Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
  

  Presenting Author: Dean Follmann, PhD (he/him/his) – National Institute of Allergy and Infectious Disease

  Co-Author: Xiaowei Wang, PhD – Moderna, Inc.

  Co-Author: Peter Gilbert, PhD – Fred Hutchinson Cancer Center

  Co-Author: Lindsey R. Baden, MD – Brigham and Women's Hospital

  Co-Author: Hana M. El Sahly, MD – Baylor College of Medicine

  Co-Author: Brandon Essink, M.D. – Meridian Clinical Research

  Co-Author: Mary Marovich, M.D. – National Institute of Allergy and Infectious Diseases, National Institutes of Health

  Co-Author: Holly Janes, PhD – Fred Hutchinson Cancer Research Center

  Co-Author: Weiping Deng, PhD – Moderna, Inc.

  Co-Author: Frances Priddy, MD, MPH – Moderna, Inc.

  Co-Author: Avika Dixit, MBBS – Moderna, Inc.

  Co-Author: Joanne Tomassini, Ph.D. – Moderna, Inc.

  Co-Author: Rituparna Das, M.D. – Moderna, Inc.

  Co-Author: Jacqueline Miller, MD – Moderna, Inc.

  Co-Author: Honghong Zhou, Ph.D. – Moderna, Inc.